Patent Board science strength of biotech firms in WSJ

The Wall Street Journal Patent Board Biotechnology Scorecard was published this week in which biotech companies & private research firms are grouped by their Patent Board science strength ranking “which is based on the scale, quality, impact, and nearness to core science of a company’s patent-based intellectual property”. What I found interesting at the first

Will JoVE’s new science blog service reinvent the genre?

The pioneer biological video publishing site JoVE (covered here many times) will soon launch a blogging platform and a community site. Nikita Bernstein, the main nerd behind JoVE is building the code and the platform – as Anne Kushnir informed me – should hopefully go live in the next couple of weeks. At least that

CIRM and NIH stem cell grants to the biotech industry

Different attitudes, same endeavors. 1. The folks at the California Institute of Regenerative Medicine (CIRM) started to offer grants for biotech companies up to $55,000 out of the 3 billion ‘hope’ dollars. San Diego Union Tribune: Industry and academia team up: For the first time in its three-year existence, the state taxpayer-funded stem cell institute

Web entrepreneurs and biotech: strangers from distant lands

Elrond: Strangers from distant lands, friends of old you have been summoned here to answer the threat of Mordor. Middle Earth stands upon the brink of destruction, none can escape it. You will unite or you will fall. Each race is bound to this fate, this one doom. Bring forth the ring, Frodo. [Frodo puts

SENS3: The stem cell marketplace by Linda Powers, Tucan Capital (slides)

Linda Powers is the managing director and co-founder of Toucan Capital Corp, a $120 million venture capital fund (SBIC) focused on seed and early-stage life science and advanced technology investments (the fund markets itself as the The Leading US Investor in Stem Cells and Regenerative Medicine). Out of here insights and facts presented on the